Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • Africa
  • Afrique

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • Africa
  • Afrique

Browsing Tag

Roche’s

9 posts
RRoche
Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD
Read More

Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD

  • 2026-04-22
Phase III METEOROID study met its primary endpoint in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)MOGAD is…
RRoche
Roche's Oncology Pipeline Shows Promise in Treating Aggressive Brain Metastases
Read More

Roche’s Oncology Pipeline Shows Promise in Treating Aggressive Brain Metastases

  • 2026-03-29
Roche’s trastuzumab, capecitabine, and tucatinib combo more than doubled median survival to 10 months in HER2+ breast cancer…
RRoche
Roche's Profitability Under Threat from European Reimbursement Clawbacks
Read More

Roche’s Profitability Under Threat from European Reimbursement Clawbacks

  • 2026-03-27
Roches, Profitability 27.03.2026 – 05:26:51 | boerse-global.de Roche defends profits via AI and efficiency…
RRoche
Roche's Strategic Pivot Gains Momentum from Immunology and Capital Restructuring
Read More

Roche’s Strategic Pivot Gains Momentum from Immunology and Capital Restructuring

  • 2026-03-21
Roche reports strong Phase III lupus data for Gazyva and finalizes share conversion. The company also increased its…
RRoche
Roche's Unwavering Dividend Commitment Amid Market Volatility
Read More

Roche’s Unwavering Dividend Commitment Amid Market Volatility

  • 2026-03-12
Roches, Unwavering 12.03.2026 – 05:15:50 | boerse-global.de Roche shareholders re-elect Chairman Severin Schwan and…
RRoche
Roche's Dividend Milestone Overshadowed by Clinical Trial Setback
Read More

Roche’s Dividend Milestone Overshadowed by Clinical Trial Setback

  • 2026-03-11
Roche’s 39th consecutive dividend increase contrasts with a Phase III trial failure for giredestrant, pressuring shares and clouding…
RRoche
Roche's Weight-Loss Ambitions Face Reality Check
Read More

Roche’s Weight-Loss Ambitions Face Reality Check

  • 2026-03-09
Roche’s Petrelintide shows 9% net weight loss in Phase II, missing high expectations. Stock and partner Zealand Pharma…
RRoche
New England Journal of Medicine publishes phase III ALLEGORY data showing Roche’s Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus
Read More

New England Journal of Medicine publishes phase III ALLEGORY data showing Roche’s Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus

  • 2026-03-06
Over three quarters of people on Gazyva/Gazyvaro plus standard therapy achieved at least a four-point improvement in SRI-4,…
RRoche
Asian Investment and Clinical Trial Scrutiny
Read More

Asian Investment and Clinical Trial Scrutiny

  • 2026-03-05
Roches, Strategic 05.03.2026 – 05:37:28 | boerse-global.de Roche reports mixed Phase III results for…
Switzerland
www.europesays.com